On August 3, TG Therapeutics declined 5.35% in regular trading, trading at $47.415/share, with turnover of approximately $43.75 million.

The decline was triggered by the company's second quarter earnings report, which revealed EPS of $0.05 versus analyst consensus estimates of $0.31–$0.33, representing a miss of approximately 85%. This marks a 70.59% decrease from EPS of $0.17 in the year-ago period. Notably, this is the third consecutive quarter in which EPS has significantly missed expectations, intensifying market concerns over the company's expense control and profitability trajectory.

While revenue of approximately $240 million exceeded the $229.7 million estimate and the company raised full-year BRIUMVI revenue guidance, the top-line beat failed to offset persistent weakness on the earnings front. The widening gap between strong commercial traction for BRIUMVI and bottom-line underperformance suggests elevated spending that investors are increasingly unwilling to overlook.

TG Therapeutics is a commercial-stage biopharmaceutical company focused on novel treatments for B-cell mediated diseases. Its core product BRIUMVI is approved in the U.S., EU, and UK for relapsing forms of multiple sclerosis.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)